Dr. Heather Landau is an oncologist and hematologist at the Memorial Sloan Kettering Cancer Center, bone marrow transplant specialist, and director of their Amyloid Program. In this video Dr. Landau reviews the history and goal of treatment for AL amyloidosis. Next she delves into detail and experiences of using high dose therapy and autologous stem cell transplant to treat light chain (AL) amyloidosis. In conclusion, she will discuss how the treatment landscape has changed based on recent advances.
Slider
ATTR Amyloidosis Treatments: Stabilizers and Silencers
Dr. Brett Sperry, cardiologist and director of the Cardiac Amyloidosis Program at Saint Luke’s Mid America Heart Institute, provides an excellent overview of FDA-approved ATTR amyloidosis treatments. He goes into detail about the biology behind silencers and stabilizers and exactly how they impair amyloidosis progression. In addition, he previews the future, summarizing new categories of drugs on the horizon.
Update: In November, 2024 the FDA approved Attruby (Acoramidis) for ATTR-CM (wild-type and hereditary/variant).
The future is indeed exciting!
